Paul Rennert

Paul Rennert

Company: Aleta Biotherapeutics

Job title: President & Chief Scientific Officer


Paul is a noted scientist and biotechnology executive with strong strategic and leadership experience. His industry expertise covers bench to IND and clinical trial development of small molecule drugs, biologics, and cellular therapeutics. His recent accomplishments include the launch of successful new biotech companies. In 2012 he engaged in the strategic analysis of cancer immuno-therapeutics with CoStim Pharmaceuticals’ executive and investment team to prioritize and launch that company’s program portfolio. In 2013 he partnered with X-Chem Inc to create XRx Discovery, a privately held drug discovery company focused on oncology, inflammation, and fibrosis. In 2016 he co-founded Aleta Biotherapeutics, a novel CAR T cell company that has since moved from bench to clinical development in under 4 years. He is deeply engaged in the biotech community, as a MassBio and ASGCT mentor, by serving on diverse Boards and as a highly sought speaker and panelist in the IO, cell therapy and investment communities. His ability to work so broadly across the industry grew from his outstanding early career at Repligen and Biogen and is further highlighted by his multiple successful drug-development campaigns, over 50 patents filed and granted, and approximately 100 peer-reviewed publications including recent publications in Nature Reviews Drug Discovery, Immunity, PNAS USA, and JCI. In 2015 he edited the book “Novel Therapeutic Approaches to the Treatment of Cancer.


Utilizing HER2 with Immune Agents: CAR-T Approach in Advanced Hematologic Cancers & Refractory Solid Tumors 12:30 pm

• Discussing patient selection and response biomarkers • Challenges of clinical translation • Latest data & future directionsRead more

day: Day One

Panel Discussion: The Evolution of Development & Use Beyond Breast Cancer 10:00 am

• Sharing insights into future directions and what to anticipate as standards evolve for HER2 drugs in the clinic • Addressing current treatment regimes and rational order of therapy • Delving into combination thoughts and current status • Understanding the current pitfalls in sequencing and selecting patients: how is HER2 high vs HER2 low evolving?…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.